Author

Corinne Betts

Observed names: Betts, Corinne A, C Betts, C. Betts, C.A. Betts, Corinne A Betts, Corinne A. Betts

Institutions: University of Oxford, NIHR Oxford Biomedical Research Centre

Observed institutions: University of Oxford, NIHR Oxford Biomedical Research Centre

ORCID: 0000-0003-0579-8843

Observed ORCID: 0000-0003-0579-8843

OpenAlex ID: A5002833384

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

2011 · Lydia Alvarez-Erviti, Yiqi Seow, et al. · Nature Biotechnology · 5,095

Delivery of therapeutic oligonucleotides with cell penetrating peptides

2015 · Prisca Boisguérin, Sébastien Deshayes, et al. · Advanced Drug Delivery Reviews · 252

PDF

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment

2012 · Corinne Betts, Amer F Saleh, et al. · Molecular Therapy — Nucleic Acids · 233

PDF

Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy

2012 · Thomas C Roberts, K Emelie M Blomberg, et al. · Molecular Therapy — Nucleic Acids · 145

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice

2009 · HaiFang Yin, Hong M Moulton, et al. · Human Molecular Genetics · 142

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

2015 · Caroline Godfrey, Sofia Muses, et al. · Human Molecular Genetics · 141

PDF

Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice

2011 · HaiFang Yin, Amer F Saleh, et al. · Molecular Therapy · 141

Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy

2015 · Tirsa Van Westering, Corinne Betts, et al. · Molecules · 110

PDF

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment

2018 · Michael J. Gait, Andrey A. Arzumanov, et al. · Nucleic Acid Therapeutics · 87

PDF

Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO

2010 · HaiFang Yin, Hong M Moulton, et al. · Molecular Therapy · 83

A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders

2024 · Besarte Vrellaku, Ilda Sethw Hassan, et al. · Molecular Therapy · 80

PDF

Optimization of Peptide Nucleic Acid Antisense Oligonucleotides for Local and Systemic Dystrophin Splice Correction in the mdx Mouse

2010 · HaiFang Yin, Corinne Betts, et al. · Molecular Therapy · 75

Diaphragm rescue alone prevents heart dysfunction in dystrophic mice

2010 · Alastair Crisp, HaiFang Yin, et al. · Human Molecular Genetics · 70

Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics

2015 · Anna M. L. Coenen-Stass, Graham McClorey, et al. · Scientific Reports · 61

PDF

Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation

2016 · Anna M.L. Coenen-Stass, Corinne A. Betts, et al. · Human Molecular Genetics · 58

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice

2015 · Corinne A. Betts, Amer F. Saleh, et al. · Scientific Reports · 55

PDF

Detection and quantification of extracellular microRNAs in murine biofluids

2014 · Thomas C Roberts, Anna M L Coenen-Stass, et al. · Biological Procedures Online · 49

PDF

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice

2018 · Lisa M. Walter, Marc-Olivier Deguise, et al. · EBioMedicine · 47

PDF

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology

2019 · Tirsa L.E. van Westering, Yulia Lomonosova, et al. · Journal of Cachexia Sarcopenia and Muscle · 30

PDF

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy

2018 · Alison M. Blain, Elizabeth Greally, et al. · PLoS ONE · 26

PDF

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency

2013 · HaiFang Yin, Prisca Boisguerin, et al. · Molecular Therapy — Nucleic Acids · 25

Cell Penetrating Peptide Delivery of Splice Directing Oligonucleotides as a Treatment for Duchenne Muscular Dystrophy

2013 · Corinne A. Betts, Matthew J.A. Wood · Current Pharmaceutical Design · 23

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy

2010 · Qingsong Wang, HaiFang Yin, et al. · The Journal of Gene Medicine · 19

CPP-Directed Oligonucleotide Exon Skipping in Animal Models of Duchenne Muscular Dystrophy

2010 · HaiFang Yin, Hong Moulton, et al. · Methods in molecular biology · 16

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice

2018 · Lisa M Walter, Christiane E Koch, et al. · Human Molecular Genetics · 15

Works count: 48

Citation count: 7,139

H-index: 22

I10-index: 28